Find clinical trials for Chronic Lymphocytic Leukemia in Milano, Lombardia
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Chronic Lymphocytic Leukemia trials near Milano, Lombardia, ITA:
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is...
Phase 1
Milan, Milano, Italy and 20 other locations
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic le...
Phase 1, Phase 2
Milan, Italy and 11 other locations
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CL...
Phase 2
Brescia, Brescia, Italy and 36 other locations
or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 3
Milan, Italy and 66 other locations
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed orig...
Phase 4
Milan, Italy and 34 other locations
monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...
Phase 1
Milan, Lombardy, Italy and 30 other locations
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Milano, Italy and 107 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Milan, Italy and 74 other locations
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...
Phase 3
Milan, Italy and 151 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Milan, Italy and 130 other locations
Clinical trials
Research sites
Resources
Legal